Beta Cat Pharmaceuticals

Beta Cat Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics that target the Wnt/beta-catenin signaling pathway, a key driver in many types of cancer. The company's lead candidate, Tegavivint (BC-2059), is a first-in-class small molecule that binds to Transducin beta-like protein 1 (TBL1), promoting the degradation of nuclear beta-catenin. By disrupting this pathway, Beta Cat aims to treat various oncology indications, including desmoid tumors and hematologic malignancies like acute myeloid leukemia. The company leverages deep expertise in the Wnt pathway to address high unmet medical needs in patients with limited treatment options.